Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | POLA1 | P09884 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL133004 | 1.00 | TSHR (0.64) | TSHRLMNAALDH1A1KMT2ARECQL | |
| SCHEMBL11389864 | 1.00 | TSHR (0.64) | TSHRLMNAALDH1A1KMT2ARECQL | |
| SCHEMBL2167453 | 1.00 | TSHR (0.64) | TSHRLMNAALDH1A1KMT2ARECQL | |
| SCHEMBL10595674 | 1.00 | TSHR (0.64) | TSHRLMNAALDH1A1KMT2ARECQL | |
| SCHEMBL3218438 | 1.00 | TSHR (0.64) | TSHRLMNAALDH1A1KMT2ARECQL | |
| SCHEMBL7829081 | 1.00 | TSHR (0.64) | TSHRLMNAALDH1A1KMT2ARECQL | |
| SCHEMBL1897460 | 1.00 | TSHR (0.64) | TSHRLMNAALDH1A1KMT2ARECQL | |
| SCHEMBL1874465 | 1.00 | TSHR (0.64) | TSHRLMNAALDH1A1KMT2ARECQL | |
| SCHEMBL127600 | 0.98 | — | — | |
| SCHEMBL51205 | 0.90 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 260 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0649431-B1 | 17-AMINO SUBSTITUTED 4-AZASTEROID 5-ALPHA-REDUCTASE INHIBITORS | MERCK & CO INC (US) | 1999-08-11 | — | — | EP | claimed |
| US-5639741-A | STEROIDS TREATING SKIN DISORDERS | MERCK & CO., INC. (US) | 1997-06-17 | — | — | US | claimed |
| EP-0778284-A2 | New 7-beta-substituted-4-aza-5alpha-androstan-3-ones as 5alpha-reductase inhibitors | MERCK & CO. INC. (US) | 1997-06-11 | — | — | EP | claimed |
| EP-0649431-A4 | 17-AMINO SUBSTITUTED 4-AZASTEROID 5-G(A)-REDUCTASE INHIBITORS. | — | 1995-05-03 | — | — | EP | claimed |
| EP-0649431-A1 | 17-AMINO SUBSTITUTED 4-AZASTEROID 5$g(a)-REDUCTASE INHIBITORS | MERCK & CO. INC. (US) | 1995-04-26 | — | — | EP | claimed |
| EP-0572166-A1 | New 7beta-substituted-4-aza-5a-androstan-3-ones as 5a-reductase inhibitors | MERCK & CO. INC. (US) | 1993-12-01 | — | — | EP | claimed |
| WO-1993023039-A1 | SUBSTITUTED 4-AZA-5A-ANDROSTAN-ONES AS 5A-REDUCTASE INHIBITORS | MERCK & CO., INC. (US) | 1993-11-25 | — | — | WO | claimed |
| WO-1993023038-A1 | 17-AMINO SUBSTITUTED 4-AZASTEROID 5α-REDUCTASE INHIBITORS | MERCK & CO., INC. (US) | 1993-11-25 | — | — | WO | claimed |
| WO-1993023420-A1 | NEW 7β-SUBSTITUTED-4-AZA-5α-ANDROSTAN-3-ONES AS 5α-REDUCTASE INHIBITORS | MERCK & CO., INC. (US) | 1993-11-25 | — | — | WO | claimed |
| EP-0230242-A2 | Substituted derivatives of 4-amino-3-hydroxy-butyric acid, process for their production, medicines containing them, and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-07-29 | — | — | EP | claimed |
| US-20240239922-A1 | PHOTOCURABLE COMPOSITION | TOKYO OHKA KOGYO CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240191003-A1 | COMPOSITION AND PHOTOSENSITIVE COMPOSITION | TOKYO OHKA KOGYO CO., LTD. (JP) | 2024-06-13 | — | — | US | disclosed |
| US-20240192593-A1 | PHOTOSENSITIVE COMPOSITION | TOKYO OHKA KOGYO CO., LTD. (JP) | 2024-06-13 | — | — | US | disclosed |
| US-11981794-B2 | Curable composition, cured product, and compound | TOKYO OHKA KOGYO CO., LTD. (JP) | 2024-05-14 | — | — | US | disclosed |
| CN-117999296-A | Composition and photosensitive composition | 东京应化工业株式会社 | 2024-05-07 | — | — | CN | disclosed |
| US-4166863-A | ACTIVE AGAINST HEMOPHILUS AND NEISSERIA | BEECHAM GROUP LIMITED (GB) | 1979-09-04 | — | — | US | disclosed |
| EP-0002371-A1 | Derivatives of monic acid A, and process for their preparation | BEECHAM GROUP PLC (GB) | 1979-06-13 | — | — | EP | disclosed |
| EP-0001914-A2 | Antibacterially active amides, process for their preparation and pharmaceutical compositions containing said amides | BEECHAM GROUP PLC (GB) | 1979-05-16 | — | — | EP | disclosed |
| US-4132750-A | RING OPENING POLYMERIZATION OF NORBORNENE DERIVATIVES | SHOWA DENKO K.K. (JP) | 1979-01-02 | — | — | US | disclosed |
| US-4102901-A | MONIC ACID ESTERS | BEECHAM GROUP LIMITED (GB) | 1978-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240192593-A1 | PHOTOSENSITIVE COMPOSITION | PPOX, ERCC1, ERCC5 | TSHR 4858/4885LMNA 514/4885ALDH1A1 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.